By Simona Mellino, Life Sciences Senior Consultant at Accenture, Basel and Vice President, WBP


The sixth Panel of the International Forum on Women’s Brain and Mental Health, focuses on novel digital products and their impact on brain and mental health. Several digital products have now received FDA approval to support the diagnosis, treatment or management of mental health and brain conditions. 

This revolutionary approach might be particularly relevant for neurology, as there is a large unmet need and digital solutions could help patients from early screening to disease management. 

However, in order to make these solutions work, they need to be validated in the target population, and account for specific differences, including sex and gender. It is crucial to keep in mind that beyond every patient there is a person with unmet medical and emotional needs.

Key questions:



Panelists will include:


Dr. Victoria Siegrist: Global Patient Partnership, Roche

Dr. Andy Bushell: CEO, Co-President OoNiDa, Switzerland

Rickard Forsman: CEO, Geras Solutions, Switzerland

Robbert Harms: Scientific Data Analyst, Altoida, Germany

Dr. Sonali Quantius: Founder of mindhealth, ETH Zurich

Dr. Priyal Sheth: VP Business Development, nQ Medical



The Moderator of the Panel is Hassan Jaroudi, Advisory Board Member of Cognomie, UK


For more information about the importance of sex and gender differences and biases in Artificial Intelligence for healthcare, read our blog by panel-owner, Simona Mellino. 

To find out more about this panel as it continues to take shape, or to participate in the conversation, follow us on social media under @womensbrainpro or register now for the International Forum on Women’s Brain and Mental Health if you have not yet done so! The Forum will offer registered participants pre-recorded talks and keynotes in addition to virtual interactive discussions by experts taking place on September 19-20, 2020.

Leave a Reply

Your email address will not be published. Required fields are marked *